UCB SA

UCB

Equity

ISIN BE0003739530 / Valor 986410

Euronext - Euronext Brussels (2024-11-18)

EUR 166.00-0.75%

UCB SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

UCB SA is a pharmaceutical company focused on transforming the lives of individuals with severe diseases by conducting research and development in the fields of neurology, immunology, and other areas. The company is dedicated to addressing unmet medical needs by leveraging scientific advancements and new technologies such as genetics, biomarkers, and human biology. UCB aims to provide differentiated solutions with unique outcomes that have tangible, positive impacts on patients' lives.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

UCB SA reported revenue growth for the fourth quarter of 2023, reaching €5.5 billion to €5.7 billion. This increase is attributed to the successful launches and continued solid contributions from the existing product portfolio.

Adjusted EBITDA

For Q4 2023, UCB SA's adjusted EBITDA was between 23.0% and 24.5%. This reflects the company's investments in global launches and its commitment to research and development to advance its late-stage and early development pipeline.

Core EPS

UCB SA's Core EPS for the fourth quarter of 2023 ranged from €3.70 to €4.40, based on an average of 190 million shares outstanding. This performance underscores the company's strong financial health and profitability.

Product Sales

UCB SA experienced strong underlying net sales growth in Q4 2023, thanks to a resilient product portfolio and new launches. Notable products include CIMZIA®, which achieved peak sales guidance of ≥ €2 billion by 2024, and BRIVIACT®, with peak sales guidance of ≥ €600 million by 2026.

Cash Flows

In Q4 2023, UCB SA's cash flow from operating activities amounted to €761 million, compared to €1,119 million in 2022. The decrease was due to higher working capital, mainly from increased inventories and outstanding receivables.

Summarized from source with an LLMView Source

Key figures

142%1Y

62.3%3Y

126%5Y

Performance

24.5%1Y

25.8%3Y

27.8%5Y

Volatility